Other: diagnostic laboratory biomarker analysis (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 74 | Prolactin secreting pituitary adenoma | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01088763 (ClinicalTrials.gov) | March 2010 | 16/3/2010 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA | Childhood Atypical Teratoid/Rhabdoid Tumor;Childhood Central Nervous System Choriocarcinoma;Childhood Central Nervous System Germinoma;Childhood Central Nervous System Mixed Germ Cell Tumor;Childhood Central Nervous System Teratoma;Childhood Central Nervous System Yolk Sac Tumor;Childhood Choroid Plexus Tumor;Childhood Craniopharyngioma;Childhood Ependymoblastoma;Childhood Grade I Meningioma;Childhood Grade II Meningioma;Childhood Grade III Meningioma;Childhood Infratentorial Ependymoma;Childhood Medulloepithelioma;Childhood Mixed Glioma;Childhood Oligodendroglioma;Childhood Supratentorial Ependymoma;Gonadotroph Adenoma;Pituitary Basophilic Adenoma;Pituitary Chromophobe Adenoma;Pituitary Eosinophilic Adenoma;Prolactin Secreting Adenoma;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Anaplastic Large Cell Lymphoma;Recurrent Childhood Brain Stem Glioma;Recurrent Childhood Central Nervous System Embryonal Tumor;Recurrent Childhood Cerebellar Astrocytoma;Recurrent Childhood Cerebral Astrocytoma;Recurrent Childhood Ependymoma;Recurrent Childhood Grade III Lymphomatoid Granulomatosis;Recurrent Childhood Large Cell Lymphoma;Recurrent Childhood Lymphoblastic Lymphoma;Recurrent Childhood Medulloblastoma;Recurrent Childhood Pineoblastoma;Recurrent Childhood Small Noncleaved Cell Lymphoma;Recurrent Childhood Spinal Cord Neoplasm;Recurrent Childhood Subependymal Giant Cell Astrocytoma;Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;Recurrent Childhood Visual Pathway and Hypothalamic Glioma;Recurrent Childhood Visual Pathway Glioma;Recurrent Pituitary Tumor;Recurrent/Refractory Childhood Hodgkin Lymphoma;T-cell Childhood Acute Lymphoblastic Leukemia;T-cell Large Granular Lymphocyte Leukemia;TSH Secreting Adenoma;Unspecified Childhood Solid Tumor, Protocol Specific | Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;Other: diagnostic laboratory biomarker analysis;Other: pharmacological study;Drug: dexamethasone | National Cancer Institute (NCI) | NULL | Terminated | 1 Year | 21 Years | Both | 129 | Phase 1 | United States;Canada |